首页 | 本学科首页   官方微博 | 高级检索  
检索        

帕病2号方对帕金森病模型大鼠中脑黑质Nrf2,HO-1表达的影响
引用本文:赵贝贝,郑春叶,雒晓东,孙玉芝,吴寿海,崔晓峰.帕病2号方对帕金森病模型大鼠中脑黑质Nrf2,HO-1表达的影响[J].中国实验方剂学杂志,2014,20(8):158-162.
作者姓名:赵贝贝  郑春叶  雒晓东  孙玉芝  吴寿海  崔晓峰
作者单位:广州中医药大学, 广州 510405;广东省中医院, 广州 510120;广东省中医院, 广州 510120;广东省中医院, 广州 510120;广东省中医院, 广州 510120;中山市黄圃人民医院, 广东 中山 528429
基金项目:广东省中医药管理局项目(20132150)
摘    要:目的:观察帕病2号方对6-羟基多巴胺(6-OHDA)所致帕金森病(PD)大鼠中脑黑质组织内核因子E2相关性因子2(Nrf2)以及下游靶基因血红加氧酶1(HO-1)的表达。方法:采用6-OHDA左侧纹状体两点注射法建立PD大鼠模型,经阿卟吗啡(APO)诱导表现为恒定右侧旋转且旋转圈数大于210 r·30 min-1视为成功PD大鼠模型。24只造模成功大鼠随机分为模型组,帕病2号方低、中、高剂量组(8.0,16.0,32.0 g·kg-1),同时设立正常组,假手术组。正常组,假手术组,模型组给予等容积蒸馏水,连续灌胃给药4周。Western blot 法检测中脑黑质Nrf2细胞核蛋白及HO-1蛋白表达。RT-PCR法检测中脑黑质Nrf2,HO-1mRNA表达。结果:与假手术组比较,模型组Nrf2细胞核蛋白,HO-1蛋白表达上调(P<0.01),Nrf2,HO-1mRNA水平上调(P<0.01);与模型组比较,帕病2号方低、中、高剂量组大鼠中脑黑质组织Nrf2细胞核蛋白,HO-1蛋白表达明显上调(P<0.01),Nrf2,HO-1mRNA水平上调(P<0.01),帕病2号方高剂量组与中、低剂量组比较有明显差异(P<0.01)。结论:6-OHDA造模后可以激活Nrf2/HO-1信号通路;帕病2号方治疗后进一步提高Nrf2细胞核蛋白和Nrf2mRNA表达,进而上调下游靶基因HO-1蛋白及HO-1mRNA的表达,且帕病2号方高剂量组作用更为明显。

关 键 词:帕病2号方  帕金森病  核因子E2相关性因子2  血红加氧酶1
收稿时间:2013/11/24 0:00:00

Research on Expressions of Nrf2 and HO-1 in Substantia Nigra of Rats with Parkinson Disease Treated with Pabing 2 Formula
ZHAO Bei-bei,ZHENG Chun-ye,LUO Xiao-dong,SUN Yu-zhi,WU Shou-hai and CUI Xiao-feng.Research on Expressions of Nrf2 and HO-1 in Substantia Nigra of Rats with Parkinson Disease Treated with Pabing 2 Formula[J].China Journal of Experimental Traditional Medical Formulae,2014,20(8):158-162.
Authors:ZHAO Bei-bei  ZHENG Chun-ye  LUO Xiao-dong  SUN Yu-zhi  WU Shou-hai and CUI Xiao-feng
Institution:Guangzhou University of Traditional Chinese Medicine(TCM), Guangzhou 510405, China;Guangdong Province Hospital of TCM, Guangzhou 510120, China;Guangdong Province Hospital of TCM, Guangzhou 510120, China;Guangdong Province Hospital of TCM, Guangzhou 510120, China;Guangdong Province Hospital of TCM, Guangzhou 510120, China;Huangpu People's Hospital of Zhongshan City, Zhongshan 528429, China
Abstract:Objective: To investigate the effect of Pabing 2 formula on the expression of nuclear factor E2-related factor 2(Nrf2)and the hemeoxygenasel(HO-1) in substantia nigra tissue of Parkinson disease(PD) rats model induced by 6-hydroxydopamine(6-OHDA). Method: The rats were stereotaxically injected with 6-OHDA solution into the left striatum in two-site.Rats showed consistently right whirling and the number of rotation was more than 210 r·30 min-1 induced by APO, then the rat was judged as PD model.Twenty-four modeling rats successfully were randomly divided into four groups:model group, Pabing 2 formula(8.0, 16.0, 32.0 g·kg-1), at the same time, the normal group and sham group were established and given distilled water at the same volume, all with a course of 4 weeks. The nuclear Nrf2 protein and HO-1 protein levels of the substantia nigra tissue were detected by Western blot, and the mRNA levels of Nrf2 and HO-1 were determined with RT-PCR. Result: Compared with sham group, the nuclear Nrf2 protein and HO-1protein in substantia nigra tissue were significant increased(P<0.01), and the mRNA levels of Nrf2 and HO-1 were increased in model group(P<0.01). Compared with model group, the nuclear Nrf2 protein and HO-1 protein in substantia nigra tissue were significantly increased (P<0.01), and the mRNA levels of both Nrf2 and HO-1were also upregulated in Pabing 2 formula low dose group, media dose group and high dose group(P<0.01), Pabing 2 formula high dose group were significantly differences compared with the low dose group and media dose group (P<0.01). Conclusion: After 6-OHDA injection, the Nrf2/HO-1 signal transduction pathway is activated.Pabing 2 formula can enhance antioxidation ability.The underlying mechanism might be associated with activating Nrf2/HO-1 signal transduction pathway, promoting the nuclear Nrf2 protein and Nrf2 mRNA, then advancing the expression of antioxidant gene in the downstream such as HO-1 protein and HO-1 mRNA.The effects were more obvious in Pabing 2 formula high dose group.
Keywords:Pabing 2 formula  Parkinson disease  Nrf2  HO-1
本文献已被 CNKI 等数据库收录!
点击此处可从《中国实验方剂学杂志》浏览原始摘要信息
点击此处可从《中国实验方剂学杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号